Ascites News and Research RSS Feed - Ascites News and Research

New research provides new hope for liver transplant patients with recurring hepatitis C

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV). [More]

QUT researchers get new insight into ovarian cancer

Queensland scientists have made significant inroads into our understanding of the deadliest form of ovarian cancer after identifying two enzymes that make it resistant to chemotherapy. [More]
Novel device may simplify monitoring of patients' response to treatment for ovarian cancer

Novel device may simplify monitoring of patients' response to treatment for ovarian cancer

A microchip-based device developed by Massachusetts General Hospital investigators may greatly simplify the monitoring of patients' response to treatment for ovarian cancer - the most lethal form of gynecologic cancer - and certain other malignancies. [More]
GlaxoSmithKline receives CHMP positive opinion for REVOLADE

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy [More]
Interferon retreatment warning in HCV

Interferon retreatment warning in HCV

Hepatitis C virus patients who do not respond to interferon should not receive further treatment with the drug, say the authors of a new Cochrane review. [More]

Bevacizumab QoL impact highlighted in ovarian cancer patients

The ICON7 study results suggest that improved progression-free survival with bevacizumab therapy for high-risk ovarian cancer may come at the cost of health-related quality of life. [More]

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

PharmaIN Corporation and LAT Pharma LLC today announced that the US Food and Drug Administration (FDA) has granted their request for orphan-drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer. [More]

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump system in patients with ascites caused by cancer (malignant ascites). [More]
Biomedical scientists identify set of genes essential for A. baumannii gram-negative bacteria

Biomedical scientists identify set of genes essential for A. baumannii gram-negative bacteria

Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a novel, and heretofore unrecognized, set of genes essential for the growth of potentially lethal, drug-resistant bacteria. [More]

Familial predisposition ‘modestly’ affects alcoholic liver disease risk

Environmental factors appear to be the main influence on the risk for alcoholic liver disease, say researchers who found little evidence for familial predisposition to the condition. [More]

CareFusion announces acquisition of U.K. Medical

CareFusion today announced the acquisition of U.K. Medical Limited, a leading distributor of medical products to the National Health Service (NHS) and private health care sector in the United Kingdom. Terms of the deal were not disclosed. [More]
Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona. [More]

Albumin best choice for prevention of circulatory dysfunction in cirrhotic patients

Administration of albumin reduces morbidity and mortality in cirrhotic patients undergoing large-volume paracentesis due to severe ascites, according to a new meta-analysis published online today in Hepatology, the official journal of the American Association for the Study of Liver Diseases. [More]
Thrombocytosis linked to severity of ovarian cancer

Thrombocytosis linked to severity of ovarian cancer

Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at The University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine. [More]
Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California. [More]

Commercial implants of ALFApump System for refractory ascites performed at Vienna General Hospital

Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis. [More]
Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients. [More]

Measures to reduce BMI could improve outcome for patients with cirrhosis

Researchers from the United States and Europe involved in an NIH-funded multicenter study have determined that increased body mass index (BMI) is an independent predictor of clinical decompensation in patients with compensated cirrhosis, independent of portal pressure and liver function. [More]

Sequana Medical's ALFApump System for liver cirrhosis receives CE Mark approval

Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System. [More]
Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation. [More]